An analyte sensor comprising: an insertion tip configured for insertion below a tissue of a user, the insertion tip comprising: a working electrode comprising a sensing layer disposed thereon and a membrane layer disposed at least partially over the sensing layer; a substrate; and a counter electrode. Wherein a polymer layer comprising at least an immunosuppressant is disposed on an exterior surface of the working electrode, the substrate, or the counter electrode, the polymer layer being separate from the sensing layer and the membrane layer.

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.

The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

The present invention concerns treatment of pemphigus with an antibody which binds to CD20.

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

An analyte sensor comprising: an insertion tip configured for insertion below a tissue of a user, the insertion tip comprising: a working electrode comprising a sensing layer disposed thereon and a membrane layer disposed at least partially over the sensing layer; a substrate; and a counter electrode. Wherein a polymer layer comprising at least an immunosuppressant is disposed on an exterior surface of the working electrode, the substrate, or the counter electrode, the polymer layer being separate from the sensing layer and the membrane layer.